Nice, France

Frédéric Mourlane

This inventor holds 6 USPTO granted patents and 7 published patent applications and 2 EPO patents. Top assignees: Ixaka France, Alaya.bio Inc., Orphit. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frédéric Mourlane. Retrieved from https://idiyas.com/inventor/frederic-mourlane

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.9

ph-index = 1


Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Frédéric Mourlane: Innovator in Immunotherapy

Introduction

Frédéric Mourlane is a notable inventor based in Nice, France. He has made significant contributions to the field of immunotherapy, particularly through his innovative patent work. With a total of 6 patents, Mourlane's inventions focus on enhancing the efficacy and control of chimeric antigen receptor (CAR) therapies.

Latest Patents

One of Mourlane's latest patents is the "Aptamer-based CAR T-cell switch." This technology provides an advanced method for controlling CAR-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule that connects a target-binding aptamer to a CAR-binding aptamer. This system allows for targeted immunotherapy, enabling customization to any desired antigen and the ability to switch targets as needed. It also offers the flexibility to adjust dosages according to individual patient requirements and can be integrated with both in vivo and ex vivo CAR expression.

Another significant patent involves "Viral vector constructs for expression of genetic adjuvants activating the CD40 and STING pathways." These viral vectors serve as genetic immunotherapeutic agents, useful for both preventive and therapeutic vaccines. They enhance cellular and innate immune responses, particularly in the treatment of cancer and infectious diseases. The vectors include lentiviral constructs that encode various antigens and adjuvants, optimizing them for human expression.

Career Highlights

Throughout his career, Mourlane has worked with various companies, including Alaya.bio Inc. His work has been instrumental in advancing the field of immunotherapy, showcasing his commitment to innovative solutions in medicine.

Collaborations

Mourlane has collaborated with notable professionals in his field, including Cécile Bauche and Renaud Vaillant. These partnerships have contributed to the development and refinement of his groundbreaking technologies.

Conclusion

Frédéric Mourlane stands out as a pioneering inventor in the realm of immunotherapy. His innovative patents reflect a deep understanding of the complexities of immune responses and the potential for targeted therapies. His contributions are paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…